People · Operator
Named in public records as an officer, director or promoter · active 2011–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| IMMvention Therapeutix, Inc. | — | Biotechnology | Series A | $8.9M | $21.9M | 2022 |
| BioMarker Strategies LLC | — | Biotechnology | Seed | $7.9M | $23.3M | 2011 |
Mark Velleca at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Velleca on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Glenn Miller | 1 | 5 |
| Matthew Cohen | 1 | 4 |
| Jack Davis | 1 | 3 |
| Jason Rubin | 1 | 3 |
| Benjamin Scruggs | 1 | 3 |
| Joseph Klein | 1 | 2 |
| Katarzyna Kusmierz | 1 | 2 |
| Douglas Clark | 1 | 2 |
| Jerry Parrott | 1 | 1 |
| Christine Wyskiel | 1 | 1 |
| Jenny Ting | 1 | 1 |
| Marilyn Thompson | 1 | 1 |
| Anil Goyal | 1 | 1 |
| Lev Osherovich | 1 | 1 |
| Mark Vellaca | 1 | 1 |
| Paul Beresford | 1 | 1 |
| Christina Wyskiel | 1 | 1 |
| Sam Broder | 1 | 1 |
| Cy Cabradilla | 1 | 1 |
| Scott Allocco | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.